文献速递新发突发、热带与寄生虫病

固定剂量青蒿琥酯-阿莫地喹与氯喹治疗巴西亚马逊无并发症间日疟的开放标签随机对照试验

Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2016-10-20

该开放标签随机对照试验在巴西马瑙斯纳入380例无并发症间日疟患者,比较3天固定剂量青蒿琥酯-阿莫地喹(ASAQ)与氯喹的疗效与安全性,随访42天。按方案分析,第28天调整后充足临床和寄生虫学应答(ACPR)分别为100%与93.6%,第42天为97.4%与77.7%,ASAQ在多时间点显示优效且耐受性相似。

要点

  • ASAQ第42天调整后ACPR达97.4%,高于氯喹的77.7%,差异19.7%。
  • 基于氯喹血药浓度估计,至第42天氯喹耐药率为11.5%。

核心结论

  • ASAQ对氯喹耐药间日疟显示高效,是该研究地区合适的替代方案。

研究设计与样本

  • 开放标签随机对照试验,2012至2013年在巴西马瑙斯纳入380例无并发症间日疟患者,随访42天,比较3天固定剂量ASAQ与氯喹,主要终点为第28天ACPR并进行基因型调整。

主要发现

  • 按方案分析第28天调整后ACPR为ASAQ 100%(165/165)与氯喹93.6%(161/172),差异6.4%(95%CI 2.7%;10.1%)。
  • 按方案分析第42天ACPR为ASAQ 97.4%(151/155)与氯喹77.7%(129/166),差异19.7%(95%CI 12.9%;26.5%)。
  • 除意向性治疗第28天评估外,ASAQ在ACPR上均显示优效,且寄生虫血症和发热清除更快。
  • 基于氯喹血药浓度测量,至第42天氯喹耐药率估计为11.5%(95%CI 7.5-17.3)。

关键数值与推荐

  • 第28天调整后ACPR:ASAQ 100%(165/165),氯喹93.6%(161/172),差异6.4%(95%CI 2.7%;10.1%)。
  • 第42天ACPR:ASAQ 97.4%(151/155),氯喹77.7%(129/166),差异19.7%(95%CI 12.9%;26.5%)。
  • 氯喹耐药率估计11.5%(95%CI 7.5-17.3)。

临床怎么用

  • 在氯喹耐药间日疟地区,可考虑将固定剂量ASAQ作为无并发症间日疟的替代治疗方案。
  • 治疗选择应结合当地耐药监测,且需注意本研究采用监督服药与基因型调整分析。

局限性

  • 开放标签设计可能影响安全性评估;除意向性治疗第28天评估外优效性成立,提示结果受分析人群影响。
  • 随访42天,更长随访与采用有效对照药的研究有助于更好刻画氯喹耐药特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite increasing evidence of the development of Plasmodium vivax chloroquine (CQ) resistance, there have been no trials comparing its efficacy with that of artemisinin-based combination therapies (ACTs) in Latin America. METHODS: This randomized controlled trial compared the antischizontocidal efficacy and safety of a 3-day supervised treatment of the fixed-dose combination artesunate-amodiaquine Winthrop® (ASAQ) versus CQ for treatment of uncomplicated P. vivax infection in Manaus, Brazil. Patients were followed for 42 days. Primary endpoints were adequate clinical and parasitological responses (ACPR) rates at day 28. Genotype-adjustment was performed. RESULTS: From 2012 to 2013, 380 patients were enrolled. In the per-protocol (PP) analysis, adjusted-ACPR was achieved in 100% (165/165) and 93.6% (161/172) of patients in the ASAQ and CQ arm (difference 6.4%, 95% CI 2.7%; 10.1%) at day 28 and in 97.4% (151/155) and 77.7% (129/166), respectively (difference 19.7%, 95% CI 12.9%; 26.5%), at day 42. Apart from ITT D28 assessment, superiority of ASAQ on ACPR was demonstrated. ASAQ presented faster clearance of parasitaemia and fever. Based on CQ blood level measurements, CQ resistance prevalence was estimated at 11.5% (95% CI: 7.5-17.3) up to day 42. At least one emergent adverse event (AE) was recorded for 79/190 (41x6%) in the ASAQ group and for 85/190 (44x7%) in the CQ group. Both treatments had similar safety profiles. CONCLUSIONS: ASAQ exhibited high efficacy against CQ resistant P. vivax and is an adequate alternative in the study area. Studies with an efficacious comparator, longer follow-up and genotype-adjustment can improve CQR characterization. CLINICAL TRIALS REGISTRATION: NCT01378286.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Siqueira AM, Alencar AC, Melo GC, et al. Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial. Clin Infect Dis. 2016. PMID: 27988484. doi:10.1093/cid/ciw706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。